Since the discovery of the VEGF/VEGFR signaling pathway as a master regulator of angiogenesis in development and pathology, clinical translation of anti-VEGF/VEGFR drugs has been extensively implemented in cancer treatment, making antiangiogenic therapies an established standard to combat tumor progression in some advanced cancers including metastatic RCC. The gene discussed is KDR; the disease is neoplasm.